Exelixis
Clinical trials sponsored by Exelixis, explained in plain language.
Oncology-focused biopharmaceutical company developing cancer treatments.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Can a Two-Drug combo stop colorectal cancer from coming back?
Disease control Not yet recruitingThis phase 3 trial is testing whether the experimental drug zanzalintinib, alone or combined with an immunotherapy (pembrolizumab plus berahyaluronidase alfa), can improve disease-free survival in people with stage II or III colorectal cancer who have molecular residual disease (…
Phase: PHASE3 • Sponsor: Exelixis • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Cancer patients to continue promising treatments in major extension trial
Disease control Not yet recruitingThis long-term extension study offers continued access to several cancer drugs—including cabozantinib, atezolizumab, and nivolumab—for up to 5,000 patients who benefited from them in earlier Exelixis-sponsored trials. The study focuses on monitoring safety and ongoing clinical be…
Phase: PHASE3 • Sponsor: Exelixis • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC